Two clinical trials conducted in three African nations demonstrated for the very first time that daily antiviral (ARV) drug therapy can dramatically reduce the risk of HIV infection for heterosexual couples.
The results were announced Wednesday by the Centers for Disease Control and Prevention (CDC). The “groundbreaking findings” in HIV biomedical prevention provide additional evidence that medications originally developed to save lives also offer a powerful way to prevent new infections. This strategy of providing daily ARVs to uninfected people to reduce their risk of HIV infection is called pre-exposure prophylaxis (PrEP).
PrEP offers a new strategy to prevent HIV cases acquired through heterosexual contact — the epidemic’s primary method of global transmission and a disproportionate factor in Black America.
“I was very excited to hear the results,” says Dazon Dixon Diallo, M.P.H., founder and president of the Atlanta-based Sister Love, an AIDS and reproductive-justice organization targeting Black women worldwide. “These two studies are the only two we know that are giving feedback on biomedical prevention for women. This is a real prevention option.”
The smaller study, known as TDF2, included about 1,200 sexually active, HIV-negative men and women in Botswana. The research, funded by the CDC, found that taking a once-daily tablet of the ARV Truvada — a combination of the drugs tenofovir and emtricitabine, sold by pharmaceutical company Gilead Sciences — reduced the risk of acquiring HIV infection by roughly 63 percent.
The second study, known as Partners PrEP, recruited 4,758 sero-discordant couples — those in which one partner has HIV and the other does not — in Kenya and Uganda.
For the rest click here